Insmed Incorporated
Moat Score — Insmed Incorporated
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Insmed holds over 1,400 issued patents and pending applications, with ARIKAYCE protected to at least 2035 via Orange Book patents plus 12 years of orphan/QIDP exclusivity, and BRINSUPRI similarly covered into the late 2030s, giving both marketed products strong, legally durable protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Insmed has no in-house manufacturing and depends entirely on third parties (Resilience, Patheon, Esteve Química, PARI), which is a capital-light structure but confers no structural cost advantage versus competitors making similar specialty drugs. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the only approved inhaled therapy for refractory NTM lung disease and the first approved DPP1 inhibitor for non-cystic fibrosis bronchiectasis, Insmed has meaningful pricing power in both indications, though reimbursement negotiations (e.g., unresolved national pricing in Italy for ARIKAYCE) show this power is not absolute. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Specialty respiratory and immunology drugs exhibit no network effect; a patient's or physician's value from using ARIKAYCE or BRINSUPRI does not increase as more patients are treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a refractory MAC lung disease or bronchiectasis patient stabilizes on ARIKAYCE or BRINSUPRI, physicians are often reluctant to switch a working regimen, but neither drug involves technical lock-in, and a patient could move to a future competing therapy if one is approved and reimbursed. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Both target indications are niche enough (an estimated ~500,000 US bronchiectasis patients, a smaller refractory MAC population) that the market may not support many directly competing approved therapies, but Insmed's own pipeline disclosures acknowledge other DPP1 inhibitors and treprostinil formulations are already in development. |